Evidence map›Paper›PMID 34904468›Full record

ArticleThe Journal of international medical research2021

Potential predictive value of plasma heat shock protein 90α in lung cancer.

Xiaoqian Li, Xuesong Tong, Bin Liu, Zeng Li, Jing Ding, Jiang Li, Min Zheng, Yuke Tian, Siyou Yan, Meiling Huang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of international medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Xiaoqian LiDepartment of Medical Oncology, 71067Sun Yat-sen University Cancer Center, Sun Yat-sen University Cancer Center, Guangzhou, State Key Laboratory of Oncology in Southern China, and Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
Xuesong TongCriminal Science and Technology Office in Criminal Police Brigade of Pidu Branch of Chengdu Public Security Bureau, Chengdu, China.
Bin LiuDepartment of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, No. 55, Section 4, Renmin South Road, Chengdu, Sichuan Province, China.
Zeng LiDepartment of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, No. 55, Section 4, Renmin South Road, Chengdu, Sichuan Province, China.
Jing DingDepartment of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, No. 55, Section 4, Renmin South Road, Chengdu, Sichuan Province, China.
Jiang LiDepartment of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, No. 55, Section 4, Renmin South Road, Chengdu, Sichuan Province, China.
Min ZhengDepartment of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, No. 55, Section 4, Renmin South Road, Chengdu, Sichuan Province, China.
Yuke TianDepartment of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, No. 55, Section 4, Renmin South Road, Chengdu, Sichuan Province, China.
Siyou YanDepartment of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, No. 55, Section 4, Renmin South Road, Chengdu, Sichuan Province, China.
Meiling HuangDepartment of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, No. 55, Section 4, Renmin South Road, Chengdu, Sichuan Province, China.
Jun GeDepartment of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, No. 55, Section 4, Renmin South Road, Chengdu, Sichuan Province, China.ORCID https://orcid.org/0000-0003-3391-790X
University of Electronic Science and Technology of China · CNShanghai Public Security Bureau · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveHeat shock protein 90α (HSP90α) is associated with cancer development, progression, and metastasis. This study assessed the relationships of plasma HSP90α levels with treatment efficacy and prognosis in lung cancer.

methodsIn this retrospective cross-sectional study, 231 patients with lung cancer were enrolled from 1 September 2016 to 31 December 2019. HSP90α levels were measured before and after treatment, and their relationships with outcomes were assessed.

resultsPatients with elevated HSP90α levels before treatment had a better overall response rate (ORR, 44.1% vs. 30.6%), whereas the disease control rate did not differ between patients with elevated and normal HSP90α levels (81% vs. 78.5%). Median progression-free survival (PFS) was 6.9 months in patients with elevated baseline HSP90α levels, versus 9 months in patients with normal HSP90α levels, whereas the median overall survival (OS) times in these groups were 12 and 14.1 months, respectively. Concerning HSP90α levels after treatment, ORR (20% vs. 47.1%) and DCR (67.3% vs. 90.9%) were lower in patients with increased HSP90α levels, and PFS and OS were also significantly different between the groups.

conclusionsHSP90α levels before and after treatment were associated with treatment response and patient prognosis in lung cancer.

Indexed as

Biomarkers, TumorLung NeoplasmsCross-Sectional StudiesHSP90 Heat-Shock ProteinsHumansRetrospective StudiesBiomarkers, TumorHSP90 Heat-Shock ProteinsbiomarkerHeat shock protein 90αlung canceroverall survivalprognosisprogression-free survivaltreatment response

Identifiers

PMID34904468
PMCPMC8689615
OpenAlexW4200547929

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.